STK11 and ductal breast carcinoma in situ: We found that TAp63 is downregulated along with LKB1 and Scrib in ductal carcinoma in situ and infiltrative mammary adenocarcinomas (Figures 8a–f and Supplementary Table S4).14 We also found that TAZ is overexpressed in these samples along with its downstream target BMP4 (Figures 8g–l and Supplementary Table S4), indicating activation of the Hippo pathway in tumors deficient for TAp63.